Dias Ajoy, Kenderian Saad J, Westin Gustavo F, Litzow Mark R
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Curr Hematol Malig Rep. 2016 Aug;11(4):253-64. doi: 10.1007/s11899-016-0326-1.
Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 %. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy to improve outcomes in newly diagnosed patients. ALL cells express several antigens amenable to target therapies including CD19, CD20, CD22, and CD52. Over the last decade, there has been a surge in the development of immune therapies which target these receptors and that have induced robust responses. In this manuscript, we review these novel immune agents in the treatment of B-ALL. As these new therapies mature, the challenge going forward will be to find safe and effective combinations of these agents with chemotherapy and to determine their place in the current treatment schema.
化疗仅能治愈少数成年急性淋巴细胞白血病（ALL）患者。此外，复发的ALL预后较差，5年生存率低至7%。因此，需要开发有效的疗法来治疗复发性疾病，并将这些药物与化疗联合使用，以改善新诊断患者的治疗效果。ALL细胞表达几种适合靶向治疗的抗原，包括CD19、CD20、CD22和CD52。在过去十年中，针对这些受体的免疫疗法发展迅速，并已诱导出强烈反应。在本手稿中，我们综述了这些新型免疫药物在B-ALL治疗中的应用。随着这些新疗法的成熟，未来的挑战将是找到这些药物与化疗的安全有效组合，并确定它们在当前治疗方案中的地位。
